PI3-kinase has a crucial role in transformation mediated by the oncogenic c-Kit mutant D816V. In this study, we demonstrate that the c-Kit/D816V-mediated cell survival is dependent on an intact direct binding of PI3-kinase to c-Kit. However, mutation of this binding site had little effect on the PI3-kinase activity in the cells, suggesting that c-Kit/D816V-mediated cell survival is dependent on PI3-kinase but not its kinase activity. Furthermore, inhibition of the lipid kinase activity of PI3-kinase led only to a slight inhibition of cell survival. Knockdown of the predominant PI3-kinase isoform p110d in c-Kit/D816V-expressing Ba/F3 cells led to reduced cell transformation both in vitro and in vivo without affecting the overall PI3-kinase activity. This suggests that p110d has a lipid-kinaseindependent role in c-Kit/D816V-mediated cell transformation. We furthermore demonstrate that p110d is phosphorylated at residues Y524 and S1039 and that phosphorylation requires an intact binding site for PI3-kinase in c-Kit/D816V. Overexpression of p110d carrying the Y523F and S1038A mutations significantly reduced c-Kit/D816V-mediated cell survival and proliferation. Taken together, our results demonstrate an important lipid-kinase-independent role of p110d in c-Kit/D816V-mediated cell transformation. This furthermore suggests that p110d could be a potential diagnostic factor and selective therapeutic target for c-Kit/D816V-expressing malignancies.
INTRODUCTION
C-Kit is a type III receptor tyrosine kinase that belongs to the same subfamily as the platelet-derived growth factor (PDGF) receptors, FLT3, and the macrophage colony-stimulating factor (M-CSF) receptor. 1 When c-Kit binds its ligand stem cell factor (SCF), it dimerizes and its intrinsic tyrosine kinase is activated. Specific tyrosine residues are phosphorylated and act as docking sites for adaptors or activate signaling molecules such as Src family kinases and PI3-kinase. Of these, PI3-kinase has been shown to have an important role in c-Kit-induced cell survival, proliferation and cell adhesion. PI3-kinase is a lipid kinase that can phosphorylate the 3 0 -hydroxyl group of phosphoinositides. The lipid products of PI3-kinase act as second messengers, activating downstream signaling cascades that mediate multiple cellular responses such as cell survival, proliferation and differentiation. Based on the structure and substrate specificity, PI3-kinase can be divided into three groups: class I, II and III. Among them, the class I PI3-kinases are the most studied. Based on their activation mechanisms, class I PI3-kinases are further divided into class IA and class IB. Class IA PI3-kinase is composed of a regulatory subunit and a catalytic subunit that are constitutively associated. 3 To date, p85a, p55a, p50a, p85b and p55g have been identified as regulatory subunits and p110a, p110b and p110d as catalytic subunits of the class IA PI3-kinases. P110a and p110b are broadly expressed across tissues, whereas p110d is mainly found in lymphocytes 4 and to a lesser extent expressed in neurons. 5 In addition, p110d has also been detected in various cancer forms including lung cancer, neuroblastoma, breast cancer and melanoma. [6] [7] [8] The only member of class IB PI3-kinases that does not bind to p85 is p110g. 9 C-Kit is frequently found mutated and autoactivated in human malignancies. Mutations in gastrointestinal stromal tumors (GISTs) mainly reside in exon 11, which encodes the juxtamembrane region of c-Kit. In other malignancies, mutation at codon 816 in exon 17 is the most frequently seen mutation. This type of mutation involves the substitution of aspartic acid 816 with either a valine, tyrosine, phenylalanine, asparagine or histidine residue. Irrespective of substituting amino acid, these mutants are all constitutively active and transforming. This type of mutation has been found in mastocytosis, certain subtypes of acute myeloid leukemia (AML), germ cell tumors of the seminoma or dysgerminoma types, sinonasal nasal NK/T-cell lymphomas, intracranial teratomas and malignant melanoma. [10] [11] [12] [13] [14] [15] D816 mutations in c-Kit lead to constitutive, ligand-independent activation of its intrinsic kinase activity, and thereby constitutively activate downstream signaling pathways leading to cell transformation. 16 Imatinib (Gleevec) is a well-known inhibitor of c-Kit and has been used in the treatment of GISTs. However, c-Kit/D816V is resistant to imatinib, whereas the so-called Src/Abl dual inhibitor dasatinib can inhibit c-Kit/D816V. 17 As all c-Kit inhibitors available in the clinic also targets wild-type c-Kit and its normal physiological functions, there are unwanted side effects of treatment. Furthermore, these inhibitors can also inhibit other tyrosine kinases and even some other enzymes 18 leading to additional side effects. Therefore, there is a need to identify signaling pathways that are selectively activated by the oncogenic mutant of c-Kit but not by wild-type c-Kit, to provide a specific target for pharmacological intervention. These proteins could also constitute valuable diagnostic markers.
PI3-kinase has a key role in transformation mediated by the D816V mutant of c-Kit. 19 In this study, we show that the PI3-kinase has a role in c-Kit/D816V-mediated cell transformation that is independent of its lipid kinase activity. The D816V mutant of c-Kit, unlike the wild-type c-Kit, is able to phosphorylate p110d at Y524 and S1039. We furthermore demonstrate that this phosphorylation of p110d can promote cell transformation independent of the lipid kinase activity. These results suggest that tyrosine phosphorylation of p110d is a specific signaling event in c-Kit/ D816V-expressing cells.
RESULTS
The direct association of PI3-kinase with c-Kit/D816V but not its lipid kinase activity, is important for receptor activation as well as for cell survival The role of PI3-kinase in c-Kit/D816V-mediated cell transformation has previously been investigated by mutating the PI3-kinasebinding site Y721 of c-Kit (Y719 in mouse c-Kit) to block the direct binding of PI3-kinase to c-Kit/D816V. 19 The results indicated that Y721 in c-Kit is important for c-Kit/D816V-induced cell survival and proliferation. As the direct binding of PI3-kinase to c-Kit requires the presence of an intact YXXM motif, 20 we introduced the M724A mutation into either wild-type c-Kit or c-Kit/D816V and transfected into Ba/F3 cells. Ligand-independent cell survival and proliferation was greatly diminished in cells expressing the c-Kit/D816V/M724A mutant compared with c-Kit/D816V (Figure 1a) , which is in agreement with previous studies. 19 In contrast, phosphorylation of Akt, a target downstream of PI3-kinase, was almost unchanged (Figure 1b) . We have previously demonstrated that PI3-kinase activation by c-Kit is not solely mediated by the direct interaction with c-Kit but also through the scaffolding protein Gab2. 21 In other words, the biological phenotype in terms of survival does not match the PI3-kinase signaling activity as measured by AKT phosphorylation, suggesting that lipid-kinase-independent pathways are responsible for the effect seen. To further clarify the role of PI3-kinase enzymatic activity in these biological responses, we used the general PI3-kinase inhibitor LY294002 and the p110d-selective inhibitor IC87114 (as p110d is abundantly expressed in hematopoietic cells). Neither LY294002 nor IC87114 were able to block c-Kit/D816V-induced cell survival and proliferation, although a partial effect was seen on proliferation ( Figure 1c ). This suggests either that PI3-kinase has a lipid-kinaseindependent role or that another important signaling protein binds to the same site, Y721. However, as we used the M724A rather than the Y721F mutant, the latter is unlikely given that there is no other SH2 domain-containing protein that requires a methionine residue in position þ 3. To our surprise, the activation of c-Kit/D816V was also affected by loss of the PI3-kinase-binding site, whereas PI3-kinase inhibitors were without effect (Figures 1b  and d) . The activation of ligand-stimulated wild-type c-Kit was dramatically reduced by both the loss of PI3-kinase binding and inhibition of PI3-kinase activity (Figures 1b and c) . These data suggest that PI3-kinase can affect the signaling capability of c-Kit/ D816V in a lipid-kinase-independent fashion.
P110d has a key role in c-Kit/D816V-mediated cell transformation As p110d is the predominant isoform of class I PI3-kinase in hematopoietic cells, we sought to investigate the role of p110d in c-Kit/D816V-induced cell transformation. To this end, we used siRNA-mediated knockdown of p110d. We could demonstrate that knockdown of p110d had marginal effects on phosphorylation of Akt in both wild-type c-Kit and c-Kit/D816V-expressing Ba/F3 cells (Figure 2a ). In contrast, both cell survival and cell proliferation were inhibited (Figure 2b ). To further elucidate the role of PI3-kinase in c-Kit/D816V-mediated transformation, we performed colony formation assays in semi-solid culture. SiRNA-mediated knockdown of p110d led to the formation of far fewer as well as smaller colonies compared with control siRNA (Figure 2c) . These results clearly demonstrate that p110d is important for c-Kit/ D816V-mediated cell transformation. To further test if the effect of p110d knockdown on cell transformation was maintained in vivo, cells pre-treated with p110d siRNA, or control siRNA, were injected subcutaneously into nude mice. After 5 days, tumors were excised and measured. Tumors formed from cells with decreased levels of p110d were much smaller than tumors formed from control cells. In addition, knockdown of p110d negatively affected tumor weight (Figure 2d ). There was also a clear difference in tumor vascularization as judged by ocular observation, where knockdown of p110d led to tumors with markedly reduced blood vessel formation (Figure 2e ). Collectively, these results suggest an important role for p110d in c-Kit/D816V-mediated tumor formation.
C-Kit/D816V induces tyrosine phosphorylation of p110d independent of its lipid kinase activity To further identify how PI3-kinase contributes to c-Kit/D816V-mediated cell transformation, the regulatory subunit p85a of PI3-kinase was immunoprecipitated and probed with antibodies against phosphotyrosine and c-Kit, respectively. As expected, the binding of p85a to c-Kit was blocked by introducing the M724A mutation into wild-type c-Kit as well as to c-Kit/D186V (Figure 3a) . This is in agreement with previous studies. 20 Unexpectedly however, we noticed a heavily tyrosine-phosphorylated 110-kDa protein that co-immunoprecipitated with p85a in Ba/F3 cells expressing c-Kit/D816V but not in cells expressing wild-type c-Kit. To identify the tyrosine-phosphorylated 110-kDa protein, p85a was immunoprecipitated from cells expressing either wild-type c-Kit or c-Kit/D816V. Immunoprecipitated proteins were eluted by boiling and the released proteins were subjected to immunoprecipitation with a phosphotyrosine antibody. The 110-kDa protein was identified by mass spectrometry as the p110d subunit of PI3-kinase. The three known isoforms of the catalytic subunit of class IA PI3-kinase, p110a, p110b and p110d, all have a molecular weight of 110 kDa, and are known to associate with p85. To investigate whether p110a and p110b are also phosphorylated by c-Kit/D816V, immunoprecipitation with antibodies against p110a, p110b or p110d was performed.
Probing with a phosphotyrosine antibody demonstrated that only p110d was tyrosine-phosphorylated ( Figure 3b ), and furthermore, the phosphorylation was dependent on the direct binding of p85 to c-Kit (Figure 3c ). PI3-kinase inhibitors LY294002 and IC87114 did not inhibit the tyrosine phosphorylation of p110d, indicating that the phosphorylation is independent of the lipid kinase activity of PI3-kinase ( Figure 3d ).
P110d is phosphorylated by c-Kit/D816V at Y524 and S1039 To identify the tyrosine phosphorylation site(s) in p110d, cell lysates of c-Kit/D816V-expressing Ba/F3 cells were subjected to immunoprecipitation with a p110d antibody and the 110-kDa band was excised and analyzed by mass spectrometry. The identity of the protein as p110d was confirmed, and we found that Y524 and S1039 were phosphorylated in c-Kit/D816V-expressing Ba/F3 cells independent of SCF stimulation (Figures 4a and b) . To investigate this finding further, p110d was FLAG-tagged and the Y524F mutation was introduced. This construct was transfected into Ba/F3/c-Kit or Ba/F3/c-Kit/D816V cells. Immunoprecipitation with a FLAG antibody followed by immunoblotting with a and Ba/F3/c-Kit/D816V/M724A cells were starved for 4 h in medium without serum and IL-3 followed by SCF stimulation (100 ng/ml) for 2 min. Cells were washed once in ice-cold PBS and lysed in the lysis buffer. Total cell lysate (TCL) was probed with pAkt antibody, or c-Kit was immunoprecipitated and then probed with 4G10 (pY) antibody to evaluate c-Kit activation. Signals of pY blot were quantified and normalized by c-Kit blot to decide the relative phosphorylation of c-Kit. ***Po0.001. (c) Ba/F3/c-Kit and Ba/F3/c-Kit/D816V cells were washed thrice with PBS, resuspended in Ba/F3 complete medium without IL-3 and seeded in 24-well plates with either 100 ng/ml SCF or no cytokine as control. The media either contained PI3-kinases inhibitor LY294002 (10 mM), or p110d inhibitor IC87114 (10 mM) or no inhibitor as control. After 48 h of incubation, cells were stained with Annexin V-PE apoptosis detection kit. The living cells and apoptotic cells were counted by flow cytometry. For the cell proliferation assay, living cells were counted under the microscope. *Po0.05; ***Po0.001; ns, no significance. (d) Ba/F3/c-Kit and Ba/F3/c-Kit/D816V cells were starved for 4 h in medium without serum and IL-3, incubated with general PI3-kinases inhibitor LY294002 (10 mM) or p110d inhibitor IC87114 (10 mM) at the same time, followed by SCF stimulation (100 ng/ml) for 2 min. Total cell lysate was probed with pAkt antibody to test if the inhibitors affect the downstream signaling of PI3-kinases. Immunoprecipitated c-Kit was probed with pY antibody to evaluate the phosphorylation of c-Kit. Signals of pY blot were quantified and normalized by c-Kit blot to decide the relative phosphorylation of c-Kit. *Po0.05; ns, no significance.
p110d is essential for cell transformation J Sun et al D816V (Figure 3b) . Alignment of p110a, p110b and p110d showed that p110a and p110b have no tyrosine residue that is identical to Y524 of p110d (Figure 4e ), which could explain why p110d is the only class IA PI3-kinase that is phosphorylated by c-Kit/D816V. We have previously demonstrated that the D816V mutation of c-Kit not only activates the kinase activity but also leads to altered substrate specificity. The substrate specificity of c-Kit/D816V is similar to the specificity of Src and Abl kinases. 22 The amino-acid sequencing surrounding Y524 in p110d is characterized by the presence of an acidic amino-acid C-terminal to the tyrosine residue (YEHEKDL), which is known to characterize tyrosine residues phosphorylated by Src. Furthermore, a query of the sequence in PhosphoMotif Finder (http://www.hprd.org) revealed that the tyrosine residue is a predicted Src substrate. These results indicate that the D816V mutation of c-Kit gains a function not possessed by the wild-type receptor allowing it to phosphorylate p110d.
Apart from D816V, which is the most common activating c-Kit mutation found in human malignancies, several other mutations at aspartic acid 816 have been described in the literature. 23 To investigate whether these D816X mutants behaved in a similar fashion to D816V, the c-Kit mutants D816F, D816H and D816Y were transfected into Ba/F3 cells, and p110d was phosphorylated at Y524 by all three mutants (Figure 4f) . The difference in the intensity of p110d phosphorylation was a reflection of the overall kinase activity of the individual c-Kit mutants. The P815 cell line is a murine mast cell line that carries the D814Y mutation of c-Kit endogenously (corresponding to D816Y in the human sequence), and p110d is phosphorylated at Y524 in P815 cells as well (Figure 4g ).
Phosphorylation of p110d on Y524 and S1039 contributes to c-Kit/ D816V-mediated cell survival and proliferation independent of the lipid kinase activity of PI3-kinase To know whether the phosphorylation of p110d has a role in c-Kit/ D816V-mediated cell transformation independent of the lipid kinase activity, wild-type p110d, mutants that block the p110d is essential for cell transformation J Sun et al phosphorylation of p110d (Y524F and S1039A) and the kinasedead mutant D911A of p110d were introduced into Ba/F3/c-Kit or Ba/F3/c-Kit/D816V cells. Ba/F3/c-Kit/D816V cells expressing the Y524F mutant of p110d displayed a significantly lower cell proliferation and survival compared with cells expressing wildtype p110d (Figure 5a ), although the phosphorylation of Akt remained intact (Figure 5c ). The kinase-dead mutant of p110d inhibited proliferation of both Ba/F3/c-Kit and Ba/F3/c-Kit/D816V cells, whereas survival was only marginally affected (Figures 5a  and b) . This was concomitant with an inhibition of Akt phosphorylation (Figures 5c and d) . Both Y524 and S1039 are important for cell survival mediated by c-Kit/D816V (Figure 5a ), although phosphorylation of S1039 seems to negatively regulate Akt phosphorylation (Figure 5c ). In Ba/F3 cells expressing wildtype c-Kit, Y524 and S1039 are not important for survival and proliferation compared with wild-type p110d, as mutation of Y524 or S1039 made no significant difference in either survival or proliferation assays. These results suggest that the Y524 and S1039 phosphorylation sites are more important in the oncogenic D816V mutant of c-Kit. In addition, the D911A mutant of p110d did not block phosphorylation of p110d at Tyr 524 (Figure 5c ), which confirms that the tyrosine phosphorylation of p110d is not dependent on its lipid kinase activity.
DISCUSSION
Mastocytosis is a clonal disease of mast cells characterized by abnormal accumulation of mast cells in tissues including the skin, bone marrow, liver and the lymph nodes. Treatment of mastocytosis is palliative and mainly focuses on the relief of symptoms. 24 The D816V mutation is the most commonly found c-Kit mutation in mastocytosis patients and has been extensively studied. Several papers have demonstrated PI3-kinase to be a key mediator in c-Kit/D816V-induced cell transformation. 25, 26 In this study, we show that c-Kit/D816V-induced cell transformation is dependent on PI3-kinase but independent of its lipid kinase activity, suggesting that PI3-kinase might have other functions. We have previously shown that the D816V mutation endows c-Kit with a Src-like kinase activity, 22 indicating that the mutation does not only induce constitutive activation of the receptor but also adds functionality to the receptor. To further investigate this mechanism, we tested whether PI3-kinase can be modified by c-Kit/D816V and thereby contribute to transformation.
We found that in cells transformed by c-Kit/D816V, p110d associated with c-Kit and was strongly phosphorylated at tyrosine residues. This phosphorylation was dependent on an intact direct physical association between PI3-kinase and c-Kit. Furthermore, phosphorylation of p110d was only seen in c-Kit/D816V-expressing cells and not in cells expressing wild-type c-Kit. Thus, this phosphorylation is unique to c-Kit/D816V-transformed cells. We could furthermore demonstrate that other isoforms of PI3-kinase, such as p110a and p110b, were not tyrosine phosphorylated by c-Kit/D816V. Mass spectrometry analysis identified the site of tyrosine phosphorylation to Y524 and additionally a serine phosphorylation site, S1039, was identified.
In wild-type c-Kit-expressing cells, PI3-kinase can either be activated by direct association with phosphorylated Y721 of c-Kit or indirectly by binding to the scaffolding protein Gab2. 21 However, in terms of cells expressing c-Kit/D816V, it has great functional influence whether the binding is direct or indirect. In this study, we show that phosphorylation of p110d by c-Kit/D816V is abolished when the direct association with c-Kit is blocked.
The signaling pathways downstream of PI3-kinase are well studied, and dysregulation of these pathways contribute to oncogenesis. 27 Activating mutations of p110a and amplification of p110b have been found in tumors. Mutations of p110a lead to increased catalytic activity, and to growth factor-independent cell growth and cell transformation. 28 Studies on p110d in AML and Ba/F3/c-Kit/D816Y cells were starved, stimulated with SCF for 2 min and lysed as above, p110d and c-Kit was immunoprecipitated, respectively. The p110d precipitate was probed with pY524 antibody to evaluate the phosphorylation of p110d, and the c-Kit precipitate was probed with pY antibody to test the activation of c-Kit. (g) P815 cells were starved for 4 h in medium without serum followed by SCF stimulation for 2 min. Cells were washed once in ice-cold PBS and lysed in the lysis buffer, and p110d or c-Kit was immunoprecipitated and probed with pY523, pY, c-Kit, p110d and p85a antibodies, respectively.
p110d is essential for cell transformation J Sun et al patients have failed to detect any activating mutations. 29 In this study, we present data showing a totally new function of p110d, which is independent of its lipid kinase activity. In contrast to p110a mutations and p110b amplification that leads to higher lipid kinase activity of PI3-kinase and thereby contributes to transformation, the c-Kit/D816V phosphorylates p110d at Y524 and S1039, which contributes to c-Kit/D816V-mediated cell transformation independent of its lipid kinase activity. This is the first report of an oncogenic mutant of receptor tyrosine kinase that utilizes PI3-kinase in a manner independent of its lipid kinase activity. Currently, targeting PI3-kinase therapy focuses on the inhibition of its lipid kinase activity. From our results, we conclude that it will be necessary to block both the lipid kinase-dependent and -independent signal transduction to get a good effect on c-Kit/D816V-expressing malignancies. Phosphorylation at serine residues residing in carboxy terminus of the catalytic subunits p110b and p110d (S1070 and S1039, respectively) have been reported and was found to inhibit the lipid kinase activity of PI3- Figure 5 . Phosphorylation of p110d at Y524 and S1039 contributes to c-Kit/D816V-mediated cell survival and proliferation. (a) Ba/F3/c-Kit/ D816V cells expressing FLAG-tagged p110d were washed thrice with PBS, resuspended in Ba/F3 complete medium without IL-3, seeded in 24-well plates with either 100 ng/ml SCF, 10 ng/ml IL-3 or no cytokine as control. After 48 h of incubation, cells were stained with Annexin V-PE apoptosis detection kit and the living cells and apoptotic cells were counted by flow cytometry. For the cell proliferation assay, living cells were counted under the microscope. ***Po0.001; ns, no significance. (b) Ba/F3/c-Kit cells expressing FLAG-tagged p110d were washed thrice with PBS, resuspended in Ba/F3 complete medium without IL-3, seeded in 24-well plates with either 100 ng/ml SCF, 10 ng/ml IL-3 or no cytokine as control. After 48 h of incubation, cells were stained with Annexin V-PE apoptosis detection kit and the living cells and apoptotic cells were counted by flow cytometry. For the cell proliferation assay, living cells were counted under the microscope. ***Po0.001; ns, no significance. (c) Ba/F3/c-Kit/D816V cells expressing FLAG-tagged p110d were starved for 4 h in medium without serum and IL-3 followed by SCF stimulation (100 ng/ml) for 2 min. Total cell lysate was probed with pAkt antibody, c-Kit or FLAG was immunoprecipitated. (d) Ba/F3/c-Kit cells expressing FLAG-tagged p110d were starved for 4 h in medium without serum and IL-3 followed by SCF stimulation (100 ng/ml) for 2 min. Total cell lysate was probed with pAkt antibody, c-Kit was immunoprecipitated.
p110d is essential for cell transformation J Sun et al kinase. 30, 31 Our results confirmed the inhibitory function of phosphorylation of S1039 in p110d. In addition, blockage of S1039 phosphorylation led to a decreased cell survival although the lipid kinase activity of PI3-kinase was increased, suggesting that phosphorylation of S1039 might have additional functions.
Gain-of-function mutations of c-Kit in cancer have been widely studied. These include in-frame deletions, insertions and substitutions that through different mechanisms lead to autoactivation. Such mutations have been identified in patients with GISTs, AML, mastocytosis and testicular seminomas. In all, 70-80% of GISTs carry an activating c-Kit mutation that renders the receptor constitutively active, thus making c-Kit a clinically important therapeutic target in GISTs. 32 Most c-Kit mutations in GISTs are mapped to exon 11, which disrupts the normal interaction between the juxtamembrane domain and the kinase domain leading to activation of the receptor kinase activity. 33 More than 80% of mastocytosis patients have a mutation in exon 17 that affects aspartic acid 816 in the second part of the kinase domain of c-Kit, with D816V being the most frequently identified mutation. 34 Some AML patients also carry c-Kit/D816V. 35 The reason why GISTs usually carry mutations in exon 11 and the hematologic malignancies usually carry exon 17 mutations is not known. One possibility might be that the exon 17 mutants, such as c-Kit/D816V depend on p110d for transformation and as p110d is predominantly expressed in hematopoietic cells, this might be at least part of the explanation.
The constitutively active mutants of c-Kit have been successfully targeted with selective tyrosine kinase inhibitors. In particular, imatinib has been successful used for the treatment of cancers carrying certain mutants of c-Kit, in particular the exon 11 mutants commonly found in GISTs. However, other mutants of c-Kit such as D816V are resistant to imatinib. As the advent of imatinib, numerous tyrosine kinase inhibitors have been developed and found to inhibit also the imatinib-resistant mutants of c-Kit, such as D816V. These molecules include dasatinib and nilotinib. However, despite the promising results in the laboratory setting, none of these molecules have given any beneficial response when given to patients. 36, 37 Thus, there is a need to find novel therapeutic target for the treatment of these patients. Ideally, a signal transduction molecule that is activated solely by the oncogenic mutant of c-Kit but not by wild-type c-Kit would be a suitable target. This would potentially minimize the risk for unwanted side effect due to inhibition of normal, physiological signaling. In this study, our data suggest that the phosphorylation of p110d might be a good target for treatment of c-Kit/D816V-expressing malignancies, as this phosphorylation does not occur in normal cells. Combination treatment against several targets has in many cases improved the outcome of treatment dramatically and it can also avoid development of drug resistance and overcome unresponsiveness. 38, 39 Resistance to tyrosine kinase inhibitors could be overcome by targeting multiple levels of the signal transduction cascades. Thus, targeting p110d combined with targeting of c-Kit might improve the treatment efficacy of malignancies carrying the D816V mutation of c-Kit. Future studies will aim at elucidating the signaling pathways downstream of p110d.
MATERIALS AND METHODS

Cytokines, antibodies and peptides
Recombinant human SCF was purchased from Prospec Tany (Rehovot, Israel). The rabbit antibody KitC1, recognizing the C-terminal tail of human c-Kit, was purified as described. 40 The antibody against p110d was generated by immunizing a rabbit with the peptide CWLAHNVSKDNRQ conjugated to KLH. Antibodies recognizing pY524 of p110d were generated by immunizing rabbits with synthetic phosphopeptides corresponding to the phosphorylation sites and purified extensively by affinity chromatography. All peptides were synthesized by JPT Peptide Technology (Berlin, Germany). FLAG and b-actin antibody were purchased from Sigma (St. Louis, MI, USA). Antibodies against Akt, pErk, p110a, p110b were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). P85a antibody was purchased from US Biological (Swampscott, MA, USA). pAkt antibody was purchased from Epitomics (Burlingame, CA, USA). Phospho tyrosine antibody 4G10 was purchased from Upstate Biotechnology (Charlottesville, VA, USA). PE labeled c-Kit antibody (104D2) was purchased from Biolegend (San Diego, CA, USA).
Kits and reagents
QuikChange mutagenesis kit was purchased from Stratagene (La Jolla, CA, USA) and used according to the manufacturer's instructions. The PI3-kinase inhibitor LY294002 was purchased from Sigma and the p110d inhibitor IC87114 was from Symansis (Timaru, New Zealand). Lipofectamine 2000 was purchased from Life Technologies (Stockholm, Sweden). Chemiluminescent HRP substrate was purchased from Millipore (Billerica, MA, USA). Annexin V-PE apoptosis detection kit was purchased from BD Bioscience (San Diego, CA, USA).
Cell culture
EcoPack virus packaging cell line (Clontech), COS-1 and P815 cell line (ATCC) was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin. Ba/F3 cells (DSMZ) were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin, and 10 ng/ml recombinant murine IL-3. To establish Ba/F3 cell lines expressing c-Kit, EcoPack cells were transfected with either wild type or mutant of c-Kit constructs in pMSCVpuro vector. Supernatants were collected to infect Ba/F3 cells followed by a 2-week selection in 1.2 mg/ml puromycin. Expression levels of c-Kit were confirmed by flow cytometry and immunoblotting. C-Kitexpressing Ba/F3 cells were grown in the same medium as untransfected Ba/F3 cells. To establish Ba/F3/c-Kit or Ba/F3/c-Kit/D816V cells expressing p110d, FLAG-tagged p110d constructs in pMSCVneo vector were transfected into EcoPack cells, supernatants were collected to infect Ba/F3/c-Kit or Ba/F3/c-Kit/D816V cells followed by a 2-week selection in 0.8 mg/ml G418. Expression levels of p110d were confirmed by western blot.
Cell stimulation, immunoprecipitation and western blotting Ba/F3 cells were starved for 4 h in medium in the absence of serum and IL-3 followed by SCF stimulation (100 ng/ml) for the indicated periods of time. Cells were washed once in ice-cold phosphate-buffered saline (PBS) and lysed in a lysis buffer containing 1% Triton X-100, 25 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 2 mg/ml Trasylol, 1 mM Na 3 VO 4 and 1 mM phenylmethylsulfonyl fluoride. The lysates were centrifuged at 14 000 g for 15 min at 4 1C and supernatants were incubated end-overend with the indicated antibody for 1 h followed by incubation with protein G-Sepharose beads for 30 min at 4 1C. The immunoprecipitates were washed three times in lysis buffer, boiled for 5 min in SDS sample buffer and separated by SDS-polyacrylamide gel electrophoresis, followed by electrotransfer to Immobilon P membranes (Millipore). Membranes were blocked with 0.2% Tween-20 in PBS for 1 h at room temperature and then incubated with primary antibody overnight at 4 1C, followed by washing with 0.05% Tween-20 in PBS. Incubation with secondary horseradish peroxidase-conjugated antibody was done for 1 h at room temperature, followed by washing with 0.05% Tween-20 in PBS. The immunodetection was performed by Millipore ECL reagent.
Cell survival and proliferation assay Ba/F3 cells were washed thrice with PBS, resuspended in Ba/F3 complete medium without IL-3, seeded in 24-well plates with either 100 ng/ml SCF, 10 ng/ml IL-3 or no cytokine as control. After 48 h of incubation, cells were stained with Annexin V-PE apoptosis detection kit. The living cells and apoptotic cells were counted by flow cytometry. For the cell proliferation assay, living cells were counted under the microscope. Statistical significance was calculated by t-test or one-way analysis of variance.
